

Deciphering the Synthetic and Refolding Strategy of a Cysteine-Rich Domain in the Tumor Necrosis Factor Receptor (TNF-R) for Racemic Crystallography Analysis and D-Peptide Ligand Discovery

Alexander J. Lander, Yifu Kong, Yi Jin,* Chuanliu Wu,* and Louis Y. P. Luk*



Cite This: *ACS Bio Med Chem Au* 2024, 4, 68–76



Read Online

ACCESS |


 Metrics & More

 Article Recommendations

 Supporting Information

ABSTRACT: Many cell-surface receptors are promising targets for chemical synthesis because of their critical roles in disease development. This synthetic approach enables investigations by racemic protein crystallography and ligand discovery by mirror-image methodologies. However, due to their complex nature, the chemical synthesis of a receptor can be a significant challenge. Here, we describe the chemical synthesis and folding of a central, cysteine-rich domain of the cell-surface receptor tumor necrosis factor 1 which is integral to binding of the cytokine TNF- α , namely, TNFR-1 CRD2. Racemic protein crystallography at 1.4 Å confirmed that the native binding conformation was preserved, and TNFR-1 CRD2 maintained its capacity to bind to TNF- α ($K_D \approx 7$ nM). Encouraged by this discovery, we carried out mirror-image phage display using the enantiomeric receptor mimic and identified a D-peptide ligand for TNFR-1 CRD2 ($K_D = 1 \mu\text{M}$). This work demonstrated that cysteine-rich domains, including the central domains, can be chemically synthesized and used as mimics for investigations.

KEYWORDS: *Chemical protein synthesis, protein folding, cysteine-rich protein, mirror-image phage display, racemic protein crystallography, D-protein, D-peptide*



INTRODUCTION

Cell-surface receptors, responsible for converting external stimuli to cellular responses, are critical targets for physiological investigations as well as diagnostics and therapeutics design.¹ While recombinant routes for preparing receptors are most frequently used, chemical protein synthesis has unique advantages for research by offering atomistic control and fully breaking the barrier of chirality.² In particular, chemical synthesis enables preparation of enantiomeric proteins entirely composed of D-amino acids,³ and hence, racemic protein crystallography can be conducted for high-resolution structural analysis.⁴ Furthermore, mirror-image display methods can be performed for discovery of ultrastable D-peptide and L-RNA aptamer ligands.⁵ Despite these exciting possibilities, the chemical synthesis of cell-surface receptors presents a significant challenge.⁶ Many cell-surface receptors are lengthy, heavily post-translationally modified, and possess patches of hydrophobic segments that are prone to aggregate formation. This often results in low yields and potential contamination from misfolded byproducts.⁶

In order to simplify the process of chemical receptor synthesis, it is possible to focus on preparing a smaller but functionally relevant domain of the protein, such as terminal protein fragments⁷ or short peptide mimics.⁸ Moreover, it is


important to note that, while the ligand binding interfaces are arguably most crucial for investigations, they are often confined within the central portion of the extracellular receptors.⁹ One notable example is the tumor necrosis factor receptor 1 (TNFR-1, UniProt P19438), a key drug target in various types of inflammatory diseases.^{1a,10} Consisting of 144 residues and 12 disulfide bonds as post-translation modifications, the extracellular domain of TNFR-1 presents a challenging synthetic target. Nevertheless, the binding of TNFR-1 to its natural ligand TNF- α (UniProt P01375) primarily occurs at the central portion of the cysteine-rich domain 2 (CRD2) (Figure 1),¹¹ which contains three disulfide bonds and two pairs of beta-sheets. As this central portion of the receptor contains a significant number of TNF- α interface residues,^{11b} we envisioned that it can be synthesized individually and serve as a truncated mimic for the TNFR-1.

Received: September 13, 2023

Revised: November 14, 2023

Accepted: November 15, 2023

Published: December 11, 2023






Figure 1. Structure of the TNFR-1/TNF- α complex (PDB: 7KPB) highlighting the cysteine-rich domain 2 (CRD2, magenta) prepared in this work.

Here, we present a synthetic route to the TNFR-1 CRD2 protein domain using a one-pot chemical ligation and refolding procedure. The resulting construct manifested a significant affinity for the native TNF- α cytokine ($K_D \approx 7$ nM). The structure of TNFR-1 CRD2, determined through racemic protein crystallography, revealed the proper formation of the three disulfide bonds and showed good alignment of its backbone with the structure of the full receptor, exhibiting a backbone RMSD of 0.36 Å (PDB: 7KPB). Motivated by these observations, the enantiomeric TNFR-1 CRD2, entirely composed of D-amino acid building blocks, served as a receptor mimic in a mirror image phage display, yielding the identification of a cyclic D-peptide with a binding affinity (K_D) of 1.0 μ M for the receptor mimic with natural L-chirality.

RESULTS AND DISCUSSION

Synthesis and Folding of TNFR-1 CRD2

The preparation of the entire 45-residue TNFR-1 CRD2 polypeptide by a solid-phase peptide synthesis (SPPS) approach was first attempted (Figure 2A). However, large excesses of amino acid and repeated coupling reactions were needed at around the 30th residue (Ser72-Ser86; data not shown). This included the diastereomeric isoleucine (Ile85), which is notably costly in its D-enantiomeric form (Fmoc-D-Ile-OH £231/g, Fmoc-L-Ile-OH < £1.32/g, Sigma-Aldrich). Asp93 was also found to be prone to form aspartimide. Lastly, incorporation of the flexible C-terminal linker for immobilization (GSGSGK(biotin)) further hampered the yield in the “one-shot” approach. Accordingly, we developed a synthetic approach based on native chemical ligation (NCL; Figure 2A).¹² In this strategy, the N-terminal peptide containing the first 16 residues is prepared as a peptide hydrazide, which is then oxidized and converted to a C-terminal thioester in situ.¹³ The remaining 29 residues were incorporated using the N-terminal cysteine peptide, either alone or with a C-terminal biotin linker. Subsequently, both peptides were amenable to SPPS using just 2 equiv of amino acids during couplings, and the strategic positioning of Asp93 toward the end of the peptide chain allowed minimization of aspartimide formation (see Supporting Information S6). The ligation reaction was initially catalyzed by 4-mercaptophenylacetic acid (MPAA)¹⁴ and the resulting product was isolated via preparative HPLC for further optimization of the refolding conditions.

As the linear TNFR-1 CRD2 polypeptide contains six cysteine residues, there are 15 possible combinations for disulfide bond formation. Refolding of synthetic cysteine-rich miniproteins is often case dependent, even when structural prediction programme such as AlphaFold 2 could accurately




Figure 2. (A) Amino acid sequence and synthetic route to TNFR-1 CRD2, (B) HPLC traces monitoring one-pot ligation and refolding reaction of TNFR-1 CRD2, and (C) ESI+ mass spectra of reduced (top) and folded (bottom) TNFR-1 CRD2.

predict the structure of the folded protein.^{7b,15} Therefore, to identify the most thermodynamically stable conformer, various refolding conditions were screened, including different oxidative agents (air, DMSO, glutathione disulfide), buffer (sodium phosphate at pH 6.5, Tris at pH 8.5), temperature (4, 25 °C), and reagent concentrations (oxidative agents, protein) (Supporting Information S1). Each refolding trial involved the rapid dilution of the reduced protein. The reactions were monitored by LCMS, seeking for an upfield peak that contains a 6 Da mass loss of the oxidatively refolded miniprotein. The highest refolding yield (33% by HPLC) was achieved by preparing a solution of TNFR-1 CRD2 (0.5 mg/mL) in 6 M Gdn-HCl, 0.1 M sodium phosphate buffer (pH 6.5), 6 mM glutathione disulfide, and 60 mM glutathione, which was then rapidly diluted 5-fold with 0.1 M phosphate buffer (pH 6.5) (Table S1.1). To simplify the synthetic scheme, a one-pot approach combining ligation and refolding was developed (Figure 2B). In this approach, trifluoroethanethiol (TFET) was used as a thiol catalyst instead of MPAA.¹⁶ TFET, being volatile (boiling point 35–37 °C), could be easily removed by evaporation,¹⁶ allowing immediate refolding after ligation without purification and giving a yield of 17% (Figure 2B and C).

Validation of the Isolated TNFR-1 CRD2 as a Receptor Mimic

To validate the proper folding of TNFR-1 CRD2, we originally investigated the protein by circular dichroism spectroscopy. However, a low signal was obtained, likely due to a relatively low molar ellipticity of the short β sheet (Figure S2.1).

Subsequently, we conducted racemic protein crystallography to analyze the structure of TNFR-1 CRD2.⁴ This technique involves crystallizing small proteins from a racemic protein mixture to gain prompt access of high-resolution structural data.^{15d,17} Here, enantiomeric TNFR-1 CRD2, prepared entirely from D-amino acids (D-TNFR-1 CRD2), was synthesized following the protocol developed above with an overall yield of 16%. The racemic TNFR-1 CRD2 mixture was subjected to sparse matrix crystallization screening, and the best crystal-forming condition was identified to contain 25 mg/mL of protein racemate, 1.5 M sodium chloride, and 10% v/v ethanol. The crystal structure was solved at 1.4 Å resolution (Table S2.1), confirming the correct disulfide bond patterns with well-defined electron density (Figure 3A). The TNFR-1 CRD2 structure aligned well with that of the entire receptor TNFR-1 in complex with TNF- α ,^{11c} showing a backbone root-mean-square deviation (RMSD) of 0.36 Å across the cytokine binding interface (Figure 3B). Furthermore, the β sheet secondary structures observed in the original TNFR-1:TNF- α complex (PDB: 7KP7)^{11c} are conserved in the L-TNFR-1

CRD2 miniprotein, and are accurately reflected in the mirror image D-TNFR-1 CRD2 (Figure S2.1).

Derivatives of L- and D-TNFR-1 CRD2 were subsequently prepared by the addition of a C-terminal biotinylated linker. These proteins were immobilized onto streptavidin-coated grating coupled interferometry (GCI) chips to test their ability to recognize the native TNFR-1 ligand. The binding experiments with human TNF- α (Peprotech) showed clear binding to L-TNFR-1 CRD2 ($K_D \approx 7$ nM), with no binding to the D-counterpart (Figure 3D). Consequently, this indicated that the TNFR-1 CRD2 is structurally conserved, and its binding to TNF- α suggested that it can serve as a receptor mimic for further investigations. While terminal cysteine-rich domains have been prepared in the literature,^{7b} ligand binding often takes place at the central portions of the extracellular protein domain.^{11b,c,18} To the best of our knowledge, this is the first example in which the central binding portion of an extracellular CRD was chemically prepared and subsequently folded into its native conformation.

Application of D-TNFR-1 CRD2 as a Bait Molecule for D-peptide Inhibitor Discovery

The receptor mimic was subjected to mirror-image molecular screening as a means of seeking ligands that inhibit TNF- α binding. Peptides comprised entirely of D-amino acids (D-peptides) are attractive therapeutic candidates, as they are typically considered to be more resilient to proteolytic degradation and hence nonimmunogenic.^{3,19} A D-peptide inhibitor could be potentially tested as a candidate against TNFR-1-related inflammatory diseases localized in the protease-rich gastrointestinal tract.^{10b,20} Consequently, the D-TNFR-1 CRD2 serves as a receptor mimic in mirror-image phage display (MIPD), a molecular screening technique that exploits the concept of reflection symmetry for the discovery of peptide ligands in opposite chirality.^{5b} To conduct the experiment, D-TNFR-1 CRD2 was biotinylated at the C-terminus, immobilized onto streptavidin-coated beads, and subjected to phage display. Subsequently, bacteriophage libraries²¹ consisted of the sequence format CX₉C where X could be any canonical amino acid and terminal cysteine residues used for cyclization were tested. Following three rounds of biopanning, the peptide sequence CFHCVWLGMCEC was found to be enriched (Table S3.1) and next-generation sequencing showed that the WLGM motif was relatively conserved (Table S3.2). However, the presence of a cysteine residue at position four suggested alternative disulfide bond formation patterns. This was confirmed by an additional phage display experiment, in which the WLGM motif was fixed in the format CX₄WLGMX₂C. Following three rounds of biopanning, the most abundant peptide sequence was found to be CFHCIWLGMDEC with the re-emergence of cysteine at position 4 (Tables S3.3 and S3.4, Figure S3.1).

The inclusion of Cys4 suggested that there are three possible isomers in which the disulfide bond could form between residues 1 and 4, 1 and 11, or 4 and 11 (Figure S4.1). To isolate the most active conformer, the fully reduced peptide was oxidized in the presence of cysteine or glutathione disulfide (Figure S4.2). These conformers were isolated by HPLC for analysis by chymotrypsin digestion and LCMS analysis as well as binding to D-TNFR-1 CRD2 (Figures S4.3–S4.6). The active conformer, herein referred to as the TNFR-1 CRD2 peptide binder (TCPB), was found to contain an intramolecular disulfide bond between residues 4–11, and was cysteinylated




Figure 3. (A) σ_A -weighted $2F_o - F_c$ omit electron density map of crystallized TNFR-1 CRD2 contoured at 1σ (0.46 electrons per Å³) showing the correct disulfide bond pairings (PDB: 8P6Q), (B) overlay of L-TNFR-1 CRD2 (PDB: 8P6Q) with TNFR-1/TNF- α structure (PDB: 7KP7) reveals retention of the native binding conformation (rmsd C α = 0.36 Å), (C) mirror image folding of L- and D-TNFR-1 CRD2 observed in the racemic crystal, and (D) TNF- α binding to L-TNFR-1 CRD2 at 50–100 nM (left) and to D-TNFR-1 CRD at 50–800 nM (right). 1:1 Langmuir fit (left) is shown in black.




Figure 4. (A) Schematic overview of utilizing D-TNFR-1 CRD2 as a target in mirror image phage display for the discovery of D-peptide inhibitors. (B) Confirmed identity of the enriched peptide from phage display (TCPB). (C–E) Grating coupled interferometry (GCI) sensorgrams showing: (C) binding kinetics of L-TCPB to immobilized D-TNFR-1 CRD2, (D) binding kinetics of D-TCPB to immobilized L-TNFR-1 CRD2, and (E) TNF- α binding to immobilized sTNFR-1 with and without D-TCPB inhibitor.

at position 1 (Figure S4.7). To further characterize the TCPB, an orthogonal cysteine protection strategy using cysteine acetamidomethyl groups was implemented, coupled with solid phase deprotection and oxidation steps with iodine to yield the target conformer (Figures S4.8 and 4.9).

Full analysis of the TCPB binding kinetics was conducted by GCI using serial 2-fold dilutions of concentration and demonstrated a binding affinity (K_D) to D-TNFR-1 CRD2 of $1.6 \mu\text{M}$ (Figure 4C). The D-enantiomer of the candidate peptide binder (D-TCPB) also demonstrated reciprocal binding to the receptor mimic L-TNFR-1 CRD2 ($K_D = 1.0 \mu\text{M}$) (Figure 4D). Subsequently, D-TCPB was tested for binding to the full soluble extracellular portion of TNFR-1 (sTNFR-1, Peprotech). The binding kinetics parameters could not be obtained due to weak binding between D-TCPB and the sTNFR-1 (Figure S5.1). However, when TNF- α was flowed over immobilized sTNFR-1 in the presence of the D-TCPB, there is an observable reduction of TNF- α binding compared with the control without inhibitor, indicating competition for sTNFR-1 binding (Figure 4E).

The reduced affinity of the D-TCPB peptide for sTNFR-1 compared to the isolated CRD2 could be attributed to various factors, including steric clashes with residues outside of CRD2, interactions with the CRD2 N-terminus or interactions with neighboring charged residues on sTNFR-1 that affect long-range electrostatic associations or create electrostatic repulsion. Nevertheless, D-TCPB, serving as the first D-peptide lead, will be subjected to further refinement. Alternatively, other D-ligands can be isolated by preparing CRD2 capped at the N- and/or C-terminus or immobilized by different approaches. Subsequently, the new D-peptide lead will be tested directly for inhibition of TNFR-1/TNF- α using FRET-based (AlphaScreen™) or ELISA in vitro assays.

CONCLUSION

Here, we present a simple approach for preparing a miniprotein that can mimic the central cytokine binding segment of the tumor necrosis factor receptor 1 (TNFR-1 CRD2). Analysis by racemic protein crystallography and surface biophysical experiments demonstrated that the conformation of the receptor was retained. With a synthetically accessible TNFR-1 mimic available, we investigated its application in mirror image phage display and identified a D-peptide ligand for TNFR-1 CRD2. In clinical development, there are only a few D-peptides and L-RNA aptamers that can target naturally existing L-small proteins²² or -peptide epitopes,^{8b,23} most likely because preparation of D-protein targets is rather difficult. A simple route to D-TNFR-1 CRD2 may facilitate the discovery of ultrastable, chirally inverted molecules targeting TNFR-1, which can be potentially applied in the studies related to inflammatory diseases.^{1a,10b,c,24} For example, D-peptide ligands targeting the TNFR-1 may be coupled with a chemical reporter, such as fluorescent- or radiolabeling,²⁵ and utilized for the imaging/detection of TNFR-1 distributions.²⁶ The TNFR-1 CRD2 synthesis scheme may also find uses in other biophysical and -physiological studies such as the investigation of specific post-translational modifications²⁷ or the development of novel TNF- α biosensors.²⁸ Indeed, TNF- α is an important biomarker in numerous inflammatory diseases,²⁹ and synthetically accessible binding agents have demonstrated numerous advances in accessible biosensor technologies, such as electrochemical or fluorescent sensors.³⁰ Finally, this study illustrated that synthesis of a central cysteine-rich domain is a feasible approach and may be applicable to the studies of other medically relevant receptors.^{1d,31}

METHODS

Peptide Synthesis

Peptides were prepared by automated SPPS and purified by preparative HPLC (see Supporting Information S6 for details). Isolated peptides were analyzed by HPLC-MS using a reversed-phase C18 column (ACE, 2.1 mm × 100 mm, 110 Å, 3 μm) held at 40 °C. A 5–70% gradient of acetonitrile (+0.1% TFA) in water (+0.1% TFA) was applied over 30 min, and analyte was detected using a UV detector at 210 and 280 nm and positive electrospray ionization mass spectrometry (ESI+ MS). Purity of all peptides and proteins is ≥95% as determined by the relative integration of the target peak in the chromatogram recorded at 210 nm.

One-Pot Chemical Ligation and Refolding of TNFR-1 CRD2

Peptide hydrazide (Ser72-Ser87) (12.5 μmol), prepared by SPPS (see Supporting Information), was dissolved in 5 mL of 0.1 M sodium phosphate buffer containing 6 M Gn-HCl (pH 3.0–3.1) in a 20 mL round bottomed flask. The peptide solution was placed in an ice-salt bath at –15 °C and gently agitated by magnetic stirring for 10 min. In a 10 mL round bottomed flask, the N-terminal cysteine peptide (Cys88-Asn116 or Cys88-Asn116-Gly117-Gly121-Lys(Biotin)122) (10 μmol), prepared by SPPS (see Supporting Information S6) was dissolved in 5 mL of 0.1 M sodium phosphate buffer containing 6 M Gn-HCl (pH 6.9–7.0). The peptide hydrazide was oxidized into the corresponding peptide azide by addition of 10 equiv. NaNO₂ (aq. 0.5 M) and gently stirred at –15 °C for 20 min.³² To convert the peptide azide to the thioester, trifluoroethanethiol was added (2% v/v), the solution was removed from the ice-salt bath, and the pH was adjusted to 5.0 at room temperature. Thioester conversion was allowed to proceed for 10 min, followed by addition of the N-terminal cysteine peptide (10 μmol in 5 mL of 0.1 M phosphate, 6 M Gn-HCl, pH 6.9–7.0). The pH of the ligation mixture was adjusted to 6.8–6.9 and an additional quantity of trifluoroethanethiol was added (1% v/v, final concentration 2% v/v). The flask was then placed in a heated water bath (37 °C) and stirred for 4 h. Reaction completion was confirmed by LCMS, by taking 10 μL of the reaction mixture and quenching with 80 μL of phosphate buffer (pH 3.0) and 10 μL of TCEP (0.1 M). Following ligation completion, excess trifluoroethanethiol was removed by purging with argon for 2 h at 37 °C.¹⁶ The reaction mixture (containing reduced ligation product) was transferred to a 2 L round bottomed flask, cooled to room temperature, and diluted with 120 mL of buffer (0.1 M phosphate, 6 M Gn-HCl, pH 6.5). In a 250 mL conical flask, glutathione (120 mM) and glutathione disulfide (12 mM) were dissolved in 130 mL of buffer (0.1 M phosphate, 6 M Gn-HCl, pH 6.5). The buffer containing glutathione/glutathione disulfide was added to the diluted ligation reaction mixture (final ligation product conc. = 0.5 mg/mL) and stirred for 10 min at room temperature. The reaction mixture was then diluted 5-fold with phosphate buffer (0.1 M phosphate, pH 6.5) and stirred for 4 days at room temperature under an argon balloon. The folding reaction was monitored by LCMS, with the folded product indicated by a sharp peak with upfield retention and a molecular mass loss of 6 Da. The reaction mixture was filtered through a sintered glass funnel, and the folded protein was isolated by preparative HPLC (Final isolated yields L-TNFR-1 CRD2, 17%, 9.1 mg; D-TNFR-1 CRD2, 15%, 8.0 mg; D-TNFR-1 CRD2(biotin) at 1/10th scale (1.0 μmol), 14%, 0.84 mg; L-TNFR-1 CRD2 (biotin) at 1/10th scale (1.0 μmol), 13%, 0.78 mg).

Racemic Protein Crystallography

L-TNFR-1 CRD2 and D-TNFR-1 CRD2 were dissolved in water to a final concentration of 25 mg/mL, as determined by UV absorbance at 280 nm.³³ The peptide solutions were mixed in a 1:1 ratio to yield a 25 mg/mL racemate of DL-TNFR-1 CRD2. Half of the solution was diluted 2-fold with water to yield 12.5 mg/mL DL-TNFR-1 CRD2. The two racemate concentrations were subject to sparse-matrix crystallization screening using a Crystal Screen HT (HR2–130 from Hampton research). 50 μL of each precipitant condition was added into the wells of a SWISSCI 96-well plate. The two racemate concentrations were each mixed 1:1 with the precipitant in a 0.5 μL

sitting drop, yielding 192 crystallization drops. The best TNFR-1 CRD2 crystals were formed in the sitting drop made with 0.25 μL of 25 mg/mL DL-TNFR-1 CRD2 and 0.25 μL of precipitant composed of 1.5 M sodium chloride and 10% v/v ethanol at pH 8.5. The single, block-shaped crystals were fished from the sitting drop and dipped into cryoprotectant (2.0 M Li₂SO₄) before flash-frozen in liquid nitrogen. X-ray diffraction data were collected at the Diamond Light Source synchrotron with beamline I03 using a Dectris Eiger2 XE 16M detector. The collected data sets were processed with Xia2, and data scaling performed with Aimless.³⁴ The crystal space groups for data reductions were validated using Zandua.³⁵ The structure of the L-TNRCRD2 molecule in the protein crystal was first solved through molecular replacement in MOLREP, using residues 72–116 of the TNFR-1 X-ray crystal structure PDB: 1EXT as a search model.³⁶ This led to the calculated phases delivering a clear electron density for the D-TNFR-1 CRD2 protein molecules. The structure of D-TNFR-1 CRD2, and the remaining waters and solute, was then built through iterative rounds of manual model building using COOT³⁷ and anisotropic B-factor refinement via REFMAC.³⁸

Data collection and refinement statistics are available in the Supporting Information (Table S2.1), and the refined model of racemic TNFR-1 CRD2 has been deposited in the Protein Data Bank with the PDB code 8P6Q.

Phage Display

Briefly, a library of peptide sequences with nine randomized amino acid positions flanked by two cysteines (CX₉C) were displayed on the M13 phages, where X is any amino acid encoded by NNK. The peptides were linked to the gene-3 coat protein (pIII) via a trialanine (Ala-Ala-Ala) spacer. Gel purified DNA encoding the libraries were ligated into the pCantab SE phagemid vector, and transformed into chemically competent *E. coli* TG1. 20-fold excess of helper phage M13KO7 was used during rescue and amplification of the bacteriophages. The target protein (D-TNFR-1 CRD2) containing C-terminal GsGsGK(biotin) was immobilized (3 μg) onto streptavidin- or neutravidin-coated beads, alternating between panning rounds to reduce enrichment of nonspecific binders. Phage enrichment factor for each round is defined as the amount of phage eluted from the target well containing D-TNFR-1 CRD2 divided by the amount of phage eluted from the target well without immobilized target (Tables S3.1 and S3.3). For enriched sequences, see Tables S3.2 and S3.4.

Surface Biophysical Experiments

Grating-coupled interferometry (GCI) experiments were performed on a Creoptix WAVEsystem using 4PCH-STA WAVE sensor chips (polycarboxylate surface, streptavidin coated) or 4PCH WAVE sensor chips (polycarboxylate surface) as indicated. Chips were first conditioned with borate buffer (0.1 M sodium borate, pH 9, 1 M Sodium chloride).

For binding of TNF-α and TCPB peptides to TNFR-1 CRD2, the TNFR-1 CRD2 containing the C-terminal flexible biotinylated linker (100 μg/mL) in HBS EP buffer (10 mM HEPES, 150 mM sodium chloride, 3 mM EDTA, 0.05% surfactant P20) was immobilized onto the 4PCH-STA sensor chip by injection over the sensor surface at a 10 μL/min flow rate, followed by passivation of the surface with blank HBS EP buffer. Final immobilization densities of 2300 pg/mm² of D-TNFR-1 CRD (biotin) and 1000 pg/mm² L-TNFR-1 CRD2(biotin) were obtained. The subsequent GCI experiments were conducted in HBS EP running buffer.

TNF-α binding to the D-TNFR-1 CRD2(biotin) and L-TNFR-1 CRD2(biotin) was determined by preparing stocks of human TNF-α (Peprotech, 300–01A) in HBS-EP buffer at a 50–800 nM concentration. The cytokine solutions were passed over the immobilized D- and L-TNFR-1 CRD2 flow cells and a blank reference flow cell at a flow rate of 30 μL/min for a 100 s total injection time, followed by a 120 s dissociation phase with the HBS EP buffer. The surface was regenerated with 10 mM Glycine-HCl (pH 2) during each cycle. GCI sensorgrams are shown in Figure 3D.

L-/D-TCPB binding to the TNFR-1 CRD2 was conducted as above, using serial 2-fold dilutions (as indicated in legend, Figure 4C and D)

in HBS-EP buffer. Data were fitted with the one-to-one Langmuir binding model and binding affinity analysis conducted in the Creoptix Wave control software.

For D-TCPB binding to sTNFR-1, and the TNF- α competition assay, human sTNFR1 (animal free, Peprotech, AF-310-07) was immobilized onto a 4PCH chip via amine coupling. The polycarboxylate surface was activated by flowing a 1:1 mixture of 0.4 M EDC in H₂O and 0.1 M NHS in H₂O over all four flow channels at a rate of 10 μ L/min sTNFR-1 (10 μ g/mL) in 10 mM sodium acetate, pH 4.0, was then immobilized covalently to the sample cell at a flow of 10 μ L/min until a surface density of 500 pg/mm² was achieved. The sample and reference flow cells were subsequently blocked by injection of 1 M ethanolamine-HCl, pH 8.5, at a flow rate of 10 μ L/min. D-TCPB binding to the TNFR-1 was conducted as above, using serial 2-fold dilutions (as indicated in legend, Figure S5.1) in HBS-EP buffer (containing 0.005% P20). The surface competition assay was conducted by flowing TNF- α (30 nM) over the sTNFR-1 sensor chip, either alone or with added D-TCPB (50 μ M). The GCI sensorgrams are shown in Figure 4E.

In all experiments, blank injections were used for double referencing and a DMSO calibration curve was used for bulk correction.

For further experimental details and peptide/protein LCMS data, see the Supporting Information.

■ ASSOCIATED CONTENT

Data Availability Statement

Model coordinates and structure factors for the racemic protein crystal structure of TNFR-1 CRD2 reported in this work has been deposited in the Protein Data Bank under the accession code 8P6Q.

SI Supporting Information

The Supporting Information is available free of charge at <https://pubs.acs.org/doi/10.1021/acsbiochemau.3c00060>.

Supplementary figures and methods, HPLC and mass spectrometry data (PDF)

■ AUTHOR INFORMATION

Corresponding Authors

Louis Y. P. Luk – School of Chemistry, Cardiff University, Cardiff CF10 3AT, U.K.; orcid.org/0000-0002-7864-6261; Email: lukly@cardiff.ac.uk

Chuanliu Wu – Department of Chemistry, College of Chemistry and Chemical Engineering, The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State Key Laboratory of Physical Chemistry of Solid Surfaces, Xiamen University, Fujian Province 361005, China; orcid.org/0000-0003-2946-7299; Email: chlwu@xmu.edu.cn

Yi Jin – Manchester Institute of Biotechnology, University of Manchester, Manchester M1 7DN, U.K.; orcid.org/0000-0002-6927-4371; Email: yi.jin@manchester.ac.uk

Authors

Alexander J. Lander – School of Chemistry, Cardiff University, Cardiff CF10 3AT, U.K.; Present Address: A.J.L.: University of Basel, Molecular Pharmacy, Pharmazentrum, Klingelberstrasse 50, Basel 4056, Switzerland; orcid.org/0000-0003-0733-6597

Yifu Kong – Department of Chemistry, College of Chemistry and Chemical Engineering, The MOE Key Laboratory of Spectrochemical Analysis and Instrumentation, State Key

Laboratory of Physical Chemistry of Solid Surfaces, Xiamen University, Fujian Province 361005, China

Complete contact information is available at:

<https://pubs.acs.org/10.1021/acsbiochemau.3c00060>

Author Contributions

A.J.L. performed the synthesis and characterizations of the peptides and proteins. A.J.L. and Y.J. conducted the racemic protein crystallography. Y.K. and C.W. conducted the bacteriophage display experiments. Y.J., C.W., and L.Y.P.L. supervised the studies. A.J.L. and L.Y.P.L. wrote the manuscript. All authors contributed to editing and critical proof-reading of the manuscript. CRediT: Yifu Kong methodology.

Funding

A.J.L. is funded by an EPSRC scholarship (2107414). Y.K. and C.W. thank the National Natural Science Foundation of China (22174119) for the financial support. Y.J. thanks the Wellcome Trust (218568/Z/19/Z) for the financial support. L.Y.P.L. thanks BBSRC (BB/T015799/1) for the financial support.

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

The authors thank Diamond Light Source for access to beamline iO3 (Proposal Number: mx20147), and Dr. Pierre Rizkallah for the assistance with X-ray diffraction data collection. The authors also thank Dr. Benjamin Bax for access to the grating coupled interferometry instrument.

■ ABBREVIATIONS

TNFR-1, tumor necrosis factor receptor 1; TNF- α , tumor necrosis factor α ; CRD, cysteine-rich domain; SPPS, solid-phase peptide synthesis; MPAA, 4-mercaptophenylacetic acid; TFET, trifluoroethanthiol; MIPD, mirror-image phage display; TCPB, TNFR-1 CRD2 peptide binder; GCI, grating-coupled interferometry

■ REFERENCES

- (1) (a) Doss, G. P.; Agoramorthy, G.; Chakraborty, C. TNF/TNFR: drug target for autoimmune diseases and immune-mediated inflammatory diseases. *Frontiers in Bioscience* **2014**, *19* (7), 1028–1040. (b) Rosenkranz, A. A.; Slastnikova, T. A. Epidermal Growth Factor Receptor: Key to Selective Intracellular Delivery. *Biochemistry-Moscow* **2020**, *85* (9), 967–993. (c) Edward Zhou, X.; Melcher, K.; Eric Xu, H. Structural biology of G protein-coupled receptor signaling complexes. *Protein Sci.* **2019**, *28* (3), 487–501. (d) Zhou, H.; Ekmekcioglu, S.; Marks, J. W.; Mohamedali, K. A.; Asrani, K.; Phillips, K. K.; Brown, S. A.; Cheng, E.; Weiss, M. B.; Hittelman, W. N.; et al. The TWEAK receptor Fn14 is a therapeutic target in melanoma: immunotoxins targeting Fn14 receptor for malignant melanoma treatment. *Journal of Investigative Dermatology* **2013**, *133* (4), 1052–1062. (e) Maleksabet, H.; Rezaee, E.; Tabatabai, S. A. Host-Cell Surface Binding Targets in SARS-CoV-2 for Drug Design. *Curr. Pharm. Des.* **2022**, *28* (45), 3583–3591.
- (2) Tan, Y.; Wu, H.; Wei, T.; Li, X. Chemical Protein Synthesis: Advances, Challenges, and Outlooks. *J. Am. Chem. Soc.* **2020**, *142* (48), 20288–20298.
- (3) Lander, A. J.; Jin, Y.; Luk, L. Y. P. D-Peptide and D-Protein Technology: Recent Advances, Challenges, and Opportunities**. *ChemBioChem.* **2023**, *24* (4), No. e202200537.
- (4) (a) Yeates, T. O.; Kent, S. B. H. Racemic Protein Crystallography. *Annual Review of Biophysics* **2012**, *41* (1), 41–61.

- (b) Zawadzke, L. E.; Berg, J. M. The structure of a centrosymmetric protein crystal. *Proteins: Struct., Funct., Bioinf.* **1993**, *16* (3), 301–305.
- (5) (a) Eulberg, D.; Jarosch, F.; Vonhoff, S.; Klussmann, S. Spiegelmers for Therapeutic Applications – Use of Chiral Principles in Evolutionary Selection Techniques. *Aptamer Handbook* **2006**, 417–442. (b) Schumacher, T. N. M.; Mayr, L. M.; Minor, D. L.; Milhollen, M. A.; Burgess, M. W.; Kim, P. S. Identification of D-peptide ligands through mirror-image phage display. *Science* **1996**, *271* (5257), 1854–1857.
- (6) (a) Huang, D.-L.; Montigny, C.; Zheng, Y.; Beswick, V.; Li, Y.; Cao, X.-X.; Barbot, T.; Jaxel, C.; Liang, J.; Xue, M.; et al. Chemical Synthesis of Native S-Palmitoylated Membrane Proteins through Removable-Backbone-Modification-Assisted Ser/Thr Ligation. *Angew. Chem., Int. Ed.* **2020**, *59* (13), 5178–5184. (b) Johnson, E. C. B.; Kent, S. B. H. Towards the total chemical synthesis of integral membrane proteins: a general method for the synthesis of hydrophobic peptide- α thioester building blocks. *Tetrahedron Lett.* **2007**, *48* (10), 1795–1799. (c) Li, J.-B.; Tang, S.; Zheng, J.-S.; Tian, C.-L.; Liu, L. Removable Backbone Modification Method for the Chemical Synthesis of Membrane Proteins. *Acc. Chem. Res.* **2017**, *50* (5), 1143–1153. (d) Olschewski, D.; Becker, C. F. Chemical synthesis and semisynthesis of membrane proteins. *Molecular BioSystems* **2008**, *4* (7), 733–740. (e) Zheng, J.-S.; He, Y.; Zuo, C.; Cai, X.-Y.; Tang, S.; Wang, Z. A.; Zhang, L.-H.; Tian, C.-L.; Liu, L. Robust Chemical Synthesis of Membrane Proteins through a General Method of Removable Backbone Modification. *J. Am. Chem. Soc.* **2016**, *138* (10), 3553–3561. (f) Zheng, J.-S.; Yu, M.; Qi, Y.-K.; Tang, S.; Shen, F.; Wang, Z.-P.; Xiao, L.; Zhang, L.; Tian, C.-L.; Liu, L. Expedient Total Synthesis of Small to Medium-Sized Membrane Proteins via Fmoc Chemistry. *J. Am. Chem. Soc.* **2014**, *136* (9), 3695–3704.
- (7) (a) Nonaka, M.; Mabashi-Asazuma, H.; Jarvis, D. L.; Yamasaki, K.; Akama, T. O.; Nagaoka, M.; Sasai, T.; Kimura-Takagi, I.; Suwa, Y.; Yaegashi, T.; et al. Development of an orally-administrable tumor vasculature-targeting therapeutic using annexin A1-binding D-peptides. *PLoS One* **2021**, *16* (1), No. e0241157. (b) Li, Z.; Xie, J.; Peng, S.; Liu, S.; Wang, Y.; Lu, W.; Shen, J.; Li, C. Novel Strategy Utilizing Extracellular Cysteine-Rich Domain of Membrane Receptor for Constructing d-Peptide Mediated Targeted Drug Delivery Systems: A Case Study on Fn14. *Bioconjugate Chem.* **2017**, *28* (8), 2167–2179.
- (8) (a) Welch, B. D.; Francis, J. N.; Redman, J. S.; Paul, S.; Weinstock, M. T.; Reeves, J. D.; Lie, Y. S.; Whitby, F. G.; Eckert, D. M.; Hill, C. P.; et al. Design of a Potent D-Peptide HIV-1 Entry Inhibitor with a Strong Barrier to Resistance. *Journal of Virology* **2010**, *84* (21), 11235–11244. (b) Redman, J. S.; Francis, J. N.; Marquardt, R.; Papac, D.; Mueller, A. L.; Eckert, D. M.; Welch, B. D.; Kay, M. S. Pharmacokinetic and Chemical Synthesis Optimization of a Potent d-Peptide HIV Entry Inhibitor Suitable for Extended-Release Delivery. *Mol. Pharmaceutics* **2018**, *15* (3), 1169–1179. (c) Malhis, M.; Kaniyappan, S.; Aillaud, I.; Chandupatla, R. R.; Ramirez, L. M.; Zweckstetter, M.; Horn, A. H. C.; Mandelkow, E.; Sticht, H.; Funke, S. A. Potent Tau Aggregation Inhibitor D-Peptides Selected against Tau-Repeat 2 Using Mirror Image Phage Display. *ChemBiochem* **2021**, *22* (21), 3049–3059.
- (9) (a) Dann, C. E.; Hsieh, J. C.; Rattner, A.; Sharma, D.; Nathans, J.; Leahy, D. J. Insights into Wnt binding and signalling from the structures of two Frizzled cysteine-rich domains. *Nature* **2001**, *412* (6842), 86–90. (b) Zhan, C.; Patskovsky, Y.; Yan, Q.; Li, Z.; Ramagopal, U.; Cheng, H.; Brenowitz, M.; Hui, X.; Nathanson, S. G.; Almo, S. C. Decoy strategies: the structure of TL1A:DCR3 complex. *Structure* **2011**, *19* (2), 162–171. (c) Chan, S.; Belmar, N.; Ho, S.; Rogers, B.; Stickler, M.; Graham, M.; Lee, E.; Tran, N.; Zhang, D.; Gupta, P.; et al. An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapy. *Nature Cancer* **2022**, *3* (3), 337–354. (d) Gilbert, H. E.; Eaton, J. T.; Hannan, J. P.; Holers, V. M.; Perkins, S. J. Solution structure of the complex between CR2 SCR 1–2 and C3d of human complement: an X-ray scattering and sedimentation modelling study. *J. Mol. Biol.* **2005**, *346* (3), 859–873.
- (10) (a) Montazersaheb, S.; Hosseiniyan Khatibi, S. M.; Hejazi, M. S.; Tarhriz, V.; Farjami, A.; Ghasemian Sorbeni, F.; Farahzadi, R.; Ghasemnejad, T. COVID-19 infection: an overview on cytokine storm and related interventions. *Virology Journal* **2022**, *19* (1), 92. (b) Fischer, R.; Kontermann, R. E.; Pfizenmaier, K. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. *Frontiers in cell and developmental biology* **2020**, *8*, 401–401. (c) Palacios, Y.; Ruiz, A.; Ramón-Luing, L. A.; Ocaña-Guzman, R.; Barreto-Rodriguez, O.; Sánchez-Monciváis, A.; Tecuatzi-Cadena, B.; Regalado-García, A. G.; Pineda-Gudiño, R. D.; García-Martínez, A.; et al. Severe COVID-19 Patients Show an Increase in Soluble TNFR1 and ADAM17, with a Relationship to Mortality. *International Journal of Molecular Sciences* **2021**, *22* (16), 8423.
- (11) (a) Steeland, S.; Puimège, L.; Vandenbroucke, R. E.; Van Hauwermeiren, F.; Haustraete, J.; Devoogdt, N.; Hulpiau, P.; Leroux-Roels, G.; Laukens, D.; Meuleman, P.; et al. Generation and Characterization of Small Single Domain Antibodies Inhibiting Human Tumor Necrosis Factor Receptor 1*. *J. Biol. Chem.* **2015**, *290* (7), 4022–4037. (b) Banner, D. W.; D'Arcy, A.; Janes, W.; Gentz, R.; Schoenfeld, H. J.; Broger, C.; Loetscher, H.; Lesslauer, W. Crystal structure of the soluble human 55 kd TNF receptor-human TNF beta complex: implications for TNF receptor activation. *Cell* **1993**, *73* (3), 431–445. (c) McMillan, D.; Martínez-Fleites, C.; Porter, J.; Fox, D., 3rd; Davis, R.; Mori, P.; Ceska, T.; Carrington, B.; Lawson, A.; Bourne, T.; et al. Structural insights into the disruption of TNF-TNFR1 signalling by small molecules stabilising a distorted TNF. *Nat. Commun.* **2021**, *12* (1), 582.
- (12) Dawson, P.; Muir, T.; Clark-Lewis, I.; Kent, S. Synthesis of proteins by native chemical ligation. *Science* **1994**, *266* (5186), 776–779.
- (13) Zheng, J.-S.; Tang, S.; Qi, Y.-K.; Wang, Z.-P.; Liu, L. Chemical synthesis of proteins using peptide hydrazides as thioester surrogates. *Nat. Protoc.* **2013**, *8* (12), 2483–2495.
- (14) Johnson, E. C. B.; Kent, S. B. H. Insights into the Mechanism and Catalysis of the Native Chemical Ligation Reaction. *J. Am. Chem. Soc.* **2006**, *128* (20), 6640–6646.
- (15) (a) Kumarswamyreddy, N.; Reddy, D. N.; Robkis, D. M.; Kamiya, N.; Tsukamoto, R.; Kanaoka, M. M.; Higashiyama, T.; Oishi, S.; Bode, J. W. Chemical synthesis of Torenia plant pollen tube attractant proteins by KAHA ligation. *RSC Chemical Biology* **2022**, *3* (6), 721–727. (b) Kumarswamyreddy, N.; Nakagawa, A.; Endo, H.; Shimotohno, A.; Torii, K. U.; Bode, J. W.; Oishi, S. Chemical synthesis of the EPF-family of plant cysteine-rich proteins and late-stage dye attachment by chemoselective amide-forming ligations. *RSC Chemical Biology* **2022**, *3* (12), 1422–1431. (c) Fang, G.-M.; Chen, X.-X.; Yang, Q.-Q.; Zhu, L.-J.; Li, N.-N.; Yu, H.-Z.; Meng, X.-M. Discovery, structure, and chemical synthesis of disulfide-rich peptide toxins and their analogs. *Chin. Chem. Lett.* **2018**, *29* (7), 1033–1042. (d) Wang, C. K.; King, G. J.; Northfield, S. E.; Ojeda, P. G.; Craik, D. J. Racemic and Quasi-Racemic X-ray Structures of Cyclic Disulfide-Rich Peptide Drug Scaffolds. *Angew. Chem., Int. Ed.* **2014**, *53* (42), 11236–11241. (e) Cheneval, O.; Schroeder, C. I.; Durek, T.; Walsh, P.; Huang, Y. H.; Liras, S.; Price, D. A.; Craik, D. J. Fmoc-Based Synthesis of Disulfide-Rich Cyclic Peptides. *J. Org. Chem.* **2014**, *79* (12), 5538–5544. (f) Postma, T. M.; Albericio, F. Disulfide Formation Strategies in Peptide Synthesis. *Eur. J. Org. Chem.* **2014**, *2014* (17), 3519–3530. (g) Terrier, V. P.; Delmas, A. F.; Aucagne, V. Efficient synthesis of cysteine-rich cyclic peptides through intramolecular native chemical ligation of N-Hnb-Cys peptide cryptothioesters. *Organic & Biomolecular Chemistry* **2017**, *15* (2), 316–319. (h) Tsuda, S.; Yoshiya, T.; Mochizuki, M.; Nishiuchi, Y. Synthesis of Cysteine-Rich Peptides by Native Chemical Ligation without Use of Exogenous Thiols. *Org. Lett.* **2015**, *17* (7), 1806–1809.
- (16) Thompson, R. E.; Liu, X.; Alonso-Garcia, N.; Pereira, P. J. B.; Jolliffe, K. A.; Payne, R. J. Trifluoroethanethiol: An Additive for Efficient One-Pot Peptide Ligation–Desulfurization Chemistry. *J. Am. Chem. Soc.* **2014**, *136* (23), 8161–8164.

- (17) (a) Zuo, C.; Zhang, B.; Wu, M.; Bierer, D.; Shi, J.; Fang, G.-M. Chemical synthesis and racemic crystallization of rat C5a-desArg. *Chin. Chem. Lett.* **2020**, *31* (3), 693–696. (b) Kurgan, K. W.; Kleman, A. F.; Bingman, C. A.; Kreitler, D. F.; Weisblum, B.; Forest, K. T.; Gellman, S. H. Retention of Native Quaternary Structure in Racemic Melittin Crystals. *J. Am. Chem. Soc.* **2019**, *141* (19), 7704–7708. (c) Qu, Q.; Gao, S.; Li, Y.-M. Racemic crystal structures of peptide toxins, GsMTx4 prepared by protein total synthesis. *Journal of Peptide Science* **2018**, *24* (8–9), No. e3112. (d) Ramalho, S. D.; Wang, C. K.; King, G. J.; Byriel, K. A.; Huang, Y.-H.; Bolzani, V. S.; Craik, D. J. Synthesis, Racemic X-ray Crystallographic, and Permeability Studies of Bioactive Orbitides from *Jatropha* Species. *J. Nat. Prod.* **2018**, *81* (11), 2436–2445. (e) Gao, S.; Pan, M.; Zheng, Y.; Huang, Y. C.; Zheng, Q. Y.; Sun, D. M.; Lu, L. N.; Tan, X. D.; Tan, X. L.; Lan, H.; et al. Monomer/Oligomer Quasi-Racemic Protein Crystallography. *J. Am. Chem. Soc.* **2016**, *138* (43), 14497–14502. (f) Yeung, H.; Squire, C. J.; Yosaatmadja, Y.; Panjekar, S.; López, G.; Molina, A.; Baker, E. N.; Harris, P. W. R.; Brimble, M. A. Radiation Damage and Racemic Protein Crystallography Reveal the Unique Structure of the GASA/ Snakin Protein Superfamily. *Angew. Chem., Int. Ed.* **2016**, *55* (28), 7930–7933. (g) Pan, M.; Gao, S.; Zheng, Y.; Tan, X.; Lan, H.; Tan, X.; Sun, D.; Lu, L.; Wang, T.; Zheng, Q.; et al. Quasi-Racemic X-ray Structures of K27-Linked Ubiquitin Chains Prepared by Total Chemical Synthesis. *J. Am. Chem. Soc.* **2016**, *138* (23), 7429–7435. (h) Kreitler, D. F.; Mortenson, D. E.; Forest, K. T.; Gellman, S. H. Effects of Single α -to- β Residue Replacements on Structure and Stability in a Small Protein: Insights from Quasiracemic Crystallization. *J. Am. Chem. Soc.* **2016**, *138* (20), 6498–6505. (i) Mandal, K.; Dhayalan, B.; Avital-Shmilovici, M.; Tokmakoff, A.; Kent, S. B. H. Crystallization of Enantiomerically Pure Proteins from Quasi-Racemic Mixtures: Structure Determination by X-Ray Diffraction of Isotope-Labeled Ester Insulin and Human Insulin. *ChemBioChem.* **2016**, *17* (5), 421–425. (j) Bunker, R. D.; Mandal, K.; Bashiri, G.; Chaston, J. J.; Pentelute, B. L.; Lott, J. S.; Kent, S. B. H.; Baker, E. N. A functional role of Rv1738 in *Mycobacterium tuberculosis* persistence suggested by racemic protein crystallography. *Proc. Natl. Acad. Sci. U. S. A.* **2015**, *112* (14), 4310–4315.
- (18) (a) Mukai, Y.; Nakamura, T.; Yoshikawa, M.; Yoshioka, Y.; Tsunoda, S.; Nakagawa, S.; Yamagata, Y.; Tsutsumi, Y. Solution of the structure of the TNF-TNFR2 complex. *Science Signaling* **2010**, *3* (148), ra83. (b) Lammens, A.; Baehner, M.; Kohnert, U.; Niewoehner, J.; von Proff, L.; Schraeml, M.; Lammens, K.; Hopfner, K. P. Crystal structure of human TWEAK in complex with the Fab fragment of a neutralizing antibody reveals insights into receptor binding. *PLoS One* **2013**, *8* (5), No. e62697. (c) Wajant, H. The TWEAK-Fn14 system as a potential drug target. *Br. J. Pharmacol.* **2013**, *170* (4), 748–764.
- (19) Harrison, K.; Mackay, A. S.; Kambanis, L.; Maxwell, J. W. C.; Payne, R. J. Synthesis and applications of mirror-image proteins. *Nat. Rev. Chem.* **2023**, *7* (6), 383–404.
- (20) Delgado, M. E.; Brunner, T. The many faces of tumor necrosis factor signaling in the intestinal epithelium. *Genes & Immunity* **2019**, *20* (8), 609–626.
- (21) Wu, Y.; Fan, S.; Dong, M.; Li, J.; Kong, C.; Zhuang, J.; Meng, X.; Lu, S.; Zhao, Y.; Wu, C. Structure-guided design of CPPC-paired disulfide-rich peptide libraries for ligand and drug discovery. *Chemical Science* **2022**, *13* (26), 7780–7789.
- (22) (a) Hoellenriegel, J.; Zboralski, D.; Maasch, C.; Rosin, N. Y.; Wierda, W. G.; Keating, M. J.; Kruschinski, A.; Burger, J. A. The Spiegelmer NOX-A12, a novel CXCL12 inhibitor, interferes with chronic lymphocytic leukemia cell motility and causes chemosensitization. *Blood* **2014**, *123* (7), 1032–1039. (b) Hoehlig, K.; Maasch, C.; Shushakova, N.; Buchner, K.; Huber-Lang, M.; Purschke, W. G.; Vater, A.; Klussmann, S. A novel C5a-neutralizing mirror-image (l)-aptamer prevents organ failure and improves survival in experimental sepsis. *Molecular Therapy* **2013**, *21* (12), 2236–2246. (c) Bujko, K.; Rzeszotek, S.; Ratajczak, J.; Hoehlig, K.; Vater, A.; Ratajczak, M. Z. Inhibition of the C5a-C5aR Axis by the L-Aptamer Aon-D21 As a New Strategy to Ameliorate Uncontrolled Migration/Motility of Hematopoietic Stem Cells - Potential Therapeutic Implications for Paroxysmal Nocturnal Hemoglobinuria. *Blood* **2017**, *130*, 1188.
- (23) Nishimura, Y.; Francis, J. N.; Donau, O. K.; Jesteadt, E.; Sadjadpour, R.; Smith, A. R.; Seaman, M. S.; Welch, B. D.; Martin, M. A.; Kay, M. S. Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent D-peptide HIV entry inhibitor. *Proc. Natl. Acad. Sci. U. S. A.* **2020**, *117* (36), 22436–22442.
- (24) Bowman, E. R.; Cameron, C. M. A.; Avery, A.; Gabriel, J.; Kettelhut, A.; Hecker, M.; Sontich, C. U.; Tamilselvan, B.; Nichols, C. N.; Richardson, B.; et al. Levels of Soluble CD14 and Tumor Necrosis Factor Receptors 1 and 2 May Be Predictive of Death in Severe Coronavirus Disease 2019. *Journal of Infectious Diseases* **2021**, *223* (5), 805–810.
- (25) (a) Rosestedt, M.; Velikyan, I.; Rosenström, U.; Estrada, S.; Åberg, O.; Weis, J.; Westerlund, C.; Ingvast, S.; Korsgren, O.; Nordeman, P.; et al. Radiolabelling and positron emission tomography imaging of a high-affinity peptide binder to collagen type I. *Nuclear Medicine and Biology* **2021**, *93*, 54–62. (b) Staderini, M.; Megia-Fernandez, A.; Dhaliwal, K.; Bradley, M. Peptides for optical medical imaging and steps towards therapy. *Bioorg. Med. Chem.* **2018**, *26* (10), 2816–2826. (c) Sun, X.; Li, Y.; Liu, T.; Li, Z.; Zhang, X.; Chen, X. Peptide-based imaging agents for cancer detection. *Adv. Drug Deliv. Rev.* **2017**, *110–111*, 38–51. (d) Choksawangarn, W.; Graham, L. M.; Burke, M.; Lee, S. B.; Ostrand-Rosenberg, S.; Fenselau, C.; Edwards, N. J. Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways. *Proteomics* **2016**, *16* (13), 1881–1888.
- (26) Fu, H.; Wu, H.; Zhang, X.; Huang, J.; He, X.; Chen, L.; Guo, W.; Guo, X.; Hao, B.; Li, Y. Pre-clinical study of a TNFR1-targeted ¹⁸F probe for PET imaging of breast cancer. *Amino Acids* **2018**, *50* (3), 409–419.
- (27) (a) Murakami, M.; Kiuchi, T.; Nishihara, M.; Tezuka, K.; Okamoto, R.; Izumi, M.; Kajihara, Y. Chemical synthesis of erythropoietin glycoforms for insights into the relationship between glycosylation pattern and bioactivity. *Science Advances* **2016**, *2* (1), No. e1500678. (b) Yu, H.; Li, M.; Wen, X.; Yang, J.; Liang, X.; Li, X.; Bao, X.; Shu, J.; Ren, X.; Chen, W.; et al. Elevation of α -1,3 fucosylation promotes the binding ability of TNFR1 to TNF- α and contributes to osteoarthritic cartilage destruction and apoptosis. *Arthritis Research & Therapy* **2022**, *24* (1), 93. (c) Okamoto, R.; Mandal, K.; Sawaya, M. R.; Kajihara, Y.; Yeates, T. O.; Kent, S. B. H. (Quasi-)Racemic X-ray Structures of Glycosylated and Non-Glycosylated Forms of the Chemokine Ser-CCL1 Prepared by Total Chemical Synthesis. *Angew. Chem., Int. Ed.* **2014**, *53* (20), 5194–5198.
- (28) Bellagambi, F. G.; Baraket, A.; Longo, A.; Vatteroni, M.; Zine, N.; Bausells, J.; Fuoco, R.; Di Francesco, F.; Salvo, P.; Karanasiou, G. S.; et al. Electrochemical biosensor platform for TNF- α cytokines detection in both artificial and human saliva: Heart failure. *Sens. Actuators, B* **2017**, *251*, 1026–1033.
- (29) Lu, Y.; Zhou, Q. Q.; Xu, L. Non-Invasive Electrochemical Biosensors for TNF-alpha Cytokines Detection in Body Fluids. *Frontiers in Bioengineering and Biotechnology* **2021**, *9*, 701045.
- (30) Wang, M.; Li, L.; Zhang, L.; Zhao, J.; Jiang, Z.; Wang, W. Peptide-Derived Biosensors and Their Applications in Tumor Immunology-Related Detection. *Anal. Chem.* **2022**, *94* (1), 431–441.
- (31) (a) Park, J. S.; Kim, S. M.; Jung, K. A.; Lee, J.; Kwok, S. K.; Cho, M. L.; Park, S. H. Inhibition of the TWEAK/Fn14 pathway attenuates autoimmune arthritis in a SKG mouse model. *Histology Histopathology* **2017**, *32* (5), 481–490. (b) Oancea, E.; Teruel, M. N.; Quest, A. F. G.; Meyer, T. Green Fluorescent Protein (GFP)-tagged Cysteine-rich Domains from Protein Kinase C as Fluorescent Indicators for Diacylglycerol Signaling in Living Cells. *J. Cell Biol.* **1998**, *140* (3), 485–498. (c) Fischer, R.; Kontermann, R. E.; Pfizenmaier, K. Selective Targeting of TNF Receptors as a Novel Therapeutic Approach. *Frontiers in cell and developmental biology* **2020**, *8*, 401.

(32) Fang, G.-M.; Li, Y.-M.; Shen, F.; Huang, Y.-C.; Li, J.-B.; Lin, Y.; Cui, H.-K.; Liu, L. Protein Chemical Synthesis by Ligation of Peptide Hydrazides. *Angew. Chem., Int. Ed.* **2011**, *50* (33), 7645–7649.

(33) Anthis, N. J.; Clore, G. M. Sequence-specific determination of protein and peptide concentrations by absorbance at 205 nm. *Protein Sci.* **2013**, *22* (6), 851–858.

(34) Evans, P. R.; Murshudov, G. N. How good are my data and what is the resolution? *Acta Crystallographica. Section D, Biological Crystallography* **2013**, *69* (Pt 7), 1204–1214.

(35) Lebedev, A. A.; Isupov, M. N. Space-group and origin ambiguity in macromolecular structures with pseudo-symmetry and its treatment with the program Zanuda. *Acta Crystallographica. Section D, Biological Crystallography* **2014**, *70* (Pt 9), 2430–2443.

(36) Naismith, J. H.; Devine, T. Q.; Kohno, T.; Sprang, S. R. Structures of the extracellular domain of the type I tumor necrosis factor receptor. *Structure* **1996**, *4* (11), 1251–1262.

(37) Emsley, P.; Lohkamp, B.; Scott, W. G.; Cowtan, K. Features and development of Coot. *Acta crystallographica. Section D, Biological crystallography* **2010**, *66* (Pt 4), 486–501.

(38) Murshudov, G. N.; Skubák, P.; Lebedev, A. A.; Pannu, N. S.; Steiner, R. A.; Nicholls, R. A.; Winn, M. D.; Long, F.; Vagin, A. A. REFMAC5 for the refinement of macromolecular crystal structures. *Acta Crystallographica. Section D, Biological Crystallography* **2011**, *67* (Pt 4), 355–367.